Generic drug of Cibacene
Therapeutic class: Cardiology and angiology
Active ingredients: Benazepril
laboratory: Arrow Generic
Divisible coated tablet
Box of 90
· Slow progression of renal failure in patients with glomerular nephropathy with hypertension and proteinuria and creatinine clearance between 30 and 60 ml / min. The risk of occurrence of hyperkalemia in these patients must be taken into account, appropriate monitoring is essential.
Dosage BENAZEPRIL ACTAVIS 10 mg scored film tablet Box of 90
Benazepril tablets may be taken before, during or after meals, as food does not alter bioavailability but delays absorption.
Benazepril is given once daily.
· In the absence of prior water-soluble depletion or renal insufficiency (in routine practice): The effective dosage is 10 mg daily in a single dose.
If necessary, a non-hyperkalaemic diuretic may be combined to achieve a further decrease in blood pressure.
In arterial hypertension previously treated with diuretics:
o stop the diuretic 3 days ago to reintroduce it later if necessary,
o either administer initial doses of 2.5 mg and adjust them according to the blood pressure response.
It is recommended to dose plasma creatinine and serum potassium before treatment and within 15 days of starting therapy.
· In patients over 70 years of age (see Precautions), initiate treatment with a lower dose (5 mg / day), increased, if necessary, to 10 mg / day after month of treatment.
· In renovascular hypertension, it is recommended to start treatment at a dose of 2.5 mg / day, and adjust it to the patient's blood pressure response.
Serum creatinine and serum potassium will be monitored to detect the onset of possible renal impairment (see Precautions).
In case of renal insufficiency, the dosage of benazepril is adjusted to the degree of this insufficiency:
· If the creatinine clearance is greater than or equal to 30 ml / min, no change in dosage is necessary.
· If creatinine clearance is less than 30 ml / min, a daily dose of 5 mg daily is recommended.
In these patients, normal medical practice includes a periodic control of potassium and creatinine, for example every two months in times of therapeutic stability.
The diuretics to be associated in this case are the so-called loop diuretics.
Benazeprilat is weakly dialyzable (see Warning: hemodialysis).
In slowing the progression of renal failure in patients with glomerular nephropathy with hypertension and proteinuria and with a creatinine clearance between 30 and 60 ml / min.
The recommended dose is 10 mg daily. Monitoring of serum potassium is essential. Other antihypertensive therapies may be combined with benazepril if necessary.
This medicine should never be used in case of:
· Hypersensitivity to benazepril,
· History of angioedema (Quincke's edema) related to the use of a conversion enzyme inhibitor,
· 2nd and 3rd trimesters of pregnancy (see sections Warnings and precautions for use and Pregnancy and breast-feeding ),
· In case of bowel obstruction, due to the presence of castor oil.
This medicine is generally not recommended in case of:
· Combinations with potassium-sparing diuretics, potassium salts, estramustine and lithium (see section Interactions with other medicinal products and other forms of interaction ),
· Bilateral stenosis of the renal artery or functionally unique kidney,
Adverse effects Benazepril Actavis
Have been found:
· Headache, asthenia, vasomotor reactions, dizziness, palpitations,
Hypotension, orthostatic or not (see section Warnings and precautions for use ),
· Rash, pemphigus, Stevens Johnson syndrome,
· Digestive disorders especially due to the presence of castor oil (nausea, vomiting, abdominal pain), dysgeusia,
· Isolated cases of liver injury,
· Dry cough has been reported with the use of angiotensin-converting enzyme inhibitors.
It is characterized by its persistence as well as its disappearance at the end of treatment.
The iatrogenic etiology should be considered in the presence of this symptom.
Exceptionally: angioedema (angioedema) (see section Warnings and precautions for use ).
· Moderate increase in urea and plasma creatinine, reversible upon discontinuation of treatment. This increase is more frequently encountered in cases of stenosis of the renal arteries, arterial hypertension treated with diuretics, renal failure.
· In case of glomerular nephropathy, administration of a conversion enzyme inhibitor may cause proteinuria.
· Hyperkalemia, usually transient.
· Anemia (see Warnings and Precautions ) has been reported with angiotensin-converting enzyme inhibitors on specific sites (kidney transplant, hemodialysis). Hemolytic anemia has been observed.